Thyrocare Technologies (NSE:THYROCARE) EPS (Basic): ₹10.28 (TTM As of Mar. 2026)


NSE:THYROCARE Thyrocare Technologies Ltd NSE:THYROCARE
87 GF Score
Price ₹555.80
GF Value ₹391.48
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Thyrocare Technologies EPS (Basic)?

Thyrocare Technologies NSE:THYROCARE -0.47% 87 EPS (Basic) is ₹10.28 as of Mar. 2026. GuruFocus rates NSE:THYROCARE with a GF Score™ of 87/100 and a GF Value™ of ₹391.48 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Thyrocare Technologies's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ₹2.99. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹10.28.

Thyrocare Technologies's EPS (Diluted) for the three months ended in Mar. 2026 was ₹2.98. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹10.24.

Thyrocare Technologies's EPS without NRI for the three months ended in Mar. 2026 was ₹2.98. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 10.55.

During the past 12 months, Thyrocare Technologies's average EPS without NRIGrowth Rate was 84.50% per year. During the past 3 years, the average EPS without NRI Growth Rate was 38.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 5.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Thyrocare Technologies's highest 3-Year average EPS without NRI Growth Rate was 38.00% per year. The lowest was -18.00% per year. And the median was 12.00% per year.

Thyrocare Technologies  (NSE:THYROCARE) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Thyrocare Technologies EPS (Basic) Related Terms

Thyrocare Technologies EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Thyrocare Technologies's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thyrocare Technologies EPS (Basic) Chart

Thyrocare Technologies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.10 4.05 4.46 5.75 10.25

Thyrocare Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.39 2.45 3.02 1.82 2.99
NSE:THYROCARE
87GF Score
Thyrocare Technologies Ltd NSE:THYROCARE
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thyrocare Technologies EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Thyrocare Technologies's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(1630.4-0)/159.144
=10.24

Thyrocare Technologies's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(471.2-0)/157.592
=2.99

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹10.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₹10.28 mean?
Thyrocare Technologies (NSE:THYROCARE) has a EPS (Basic) of ₹10.28 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Thyrocare Technologies and its competitors.
Is Thyrocare Technologies' EPS (Basic) too high?
Thyrocare Technologies' current EPS (Basic) is ₹10.28. Overall, Thyrocare Technologies has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' EPS (Basic) compare to TMO and DHR?
Thyrocare Technologies' EPS (Basic) of ₹10.28 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Diagnostics & Research company?
A good EPS (Basic) depends on the Medical Diagnostics & Research industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Thyrocare Technologies and its competitors. Thyrocare Technologies's current EPS (Basic) is ₹10.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹391.48, compared to a current price of ₹555.80 — trading 42% above its estimated fair value. The current EPS (Basic) is ₹10.28. Thyrocare Technologies' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current EPS (Basic) is ₹10.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?

Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued. The current stock price of ₹555.80 is trading 42% above its estimated GF Value™ of ₹391.48. GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.

Key valuation signals for NSE:THYROCARE:

  • EPS (Basic): ₹10.28
  • GF Value™: ₹391.48 vs. price of ₹555.80 (42% above fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Thyrocare Technologies Business Description

Other Exchanges 539871:India
Address D-37/3, TTC Industrial Area, MIDC, Turbhe, Opposite Sandoz, Navi Mumbai, MH, IND, 400703
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
87GF Score

Get the complete analysis for NSE:THYROCARE

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹555.80
Price
₹391.48
GF Value